Trial of NM-505 for treatment of type 2 diabetes
Phase of Trial: Phase II
Latest Information Update: 13 May 2015
At a glance
- Drugs NM 505 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 13 May 2015 USFDA has responded positively to the company's pre-IND request to use the 505(b)(2) abbreviated pathway.
- 09 Apr 2015 New trial record
- 07 Apr 2015 According to a MicroBiome Therapeutics media release, this trial is planned in order to allow the company to seek FDA marketing approval via the expedited 505(b)(2) regulatory pathway.